Articles

Explore how Chinese innovative drugs are reshaping global pharma partnerships in 2026. From record-high upfront payments and antibody innovation to evolving deal structures and multi-therapeutic expansion, discover why global buyers are shifting from price-driven decisions to value-based collaboration.
For global buyers, the evolution of Chinese innovative drugs is no longer merely about “more choices” — it has become a matter of “higher standards.” As a long-term supplier for overseas markets, DengYueMed has observed a clear shift: international partners are increasingly evaluating Chinese innovative drugs based on value rather than price. The data from the first quarter of 2026 illustrates this transformation. 1. Rapid Rise in Upfront Payments: From Volume Growth to Price Upgrade As of Ma…

The global insulin delivery devices market is projected to grow significantly due to rising diabetes prevalence and increasing adoption of advanced insulin delivery technologies. Insulin pens and pumps dominate the market, while smart connected devices are gaining traction. North America leads the market, and Asia-Pacific is expected to witness the fastest growth. Continuous innovation, homecare adoption, and expanding healthcare infrastructure are expected to drive long-term market expansion.
The global insulin delivery devices market is experiencing strong expansion as the prevalence of diabetes continues to rise worldwide. Insulin delivery devices play a crucial role in managing blood glucose levels among diabetic patients by ensuring accurate and convenient insulin administration. These…

Learn how to source medicines from China compliantly with a complete guide to regulatory requirements, cold chain logistics, supplier verification, and digital supply chain strategies. Discover how global healthcare organizations can optimize cross-border pharmaceutical procurement efficiently and securely.
As global healthcare demand continues to grow, China has gradually become an important source of innovative medicines and generic drugs. An increasing number of medical institutions, pharmaceutical distributors, and cross-border procurement companies are paying close attention to how to source medicines from China in a compliant manner. However, due to the complexity of regulatory systems, logistics requirements, and supply chain management, establishing a stable and compliant procuremen…

The nasogastric intubation market is experiencing steady growth driven by rising chronic diseases, aging populations, and increasing demand for enteral feeding solutions. North America dominates due to advanced healthcare infrastructure, while Asia-Pacific is emerging as the fastest-growing region with strong healthcare investments. Key players are focusing on product innovation, antimicrobial tube materials, homecare feeding systems, and smart monitoring technologies to enhance patient safety and comfort. These regional dynamics and technological advancements are expected to accelerate adoption of nasogastric intubation devices globally.
Nasogastric Intubation Market Trends: Homecare Feeding, Aging Population, and Technological Innovation Driving Global Growth The nasogastric intubation ma…

In 2026, China's pharmaceutical industry has evolved from single-asset licensing to complex global healthcare collaborations. Discover how DengYueMed is navigating this transformation, offering regulatory, supply chain, and market entry solutions for Chinese innovative drugs on the global stage.
As a long-term participant deeply engaged in the cross-border pharmaceutical supply chain, DengYueMed has clearly observed through real-world business collaboration that China’s innovative drug globalization in 2026 is no longer characterized by sporadic “project out-licensing,” but rather a systematic paradigm shift toward “global healthcare collaboration.” Transaction structures are becoming increasingly complex, regional rights allocation more refined, and globally coordinated regulatory and supp…

Pharmaceutical innovation exists to improve patient outcomes. Yet between laboratory discovery and patient benefit lies a critical intermediary: conversation. The way clinical evidence is explained, challenged and contextualised in discussions with healthcare professionals (HCPs) plays a meaningful role in how new therapies are understood and adopted in practice. At the same time, the profile of those leading these conversations is changing.
A Broader Talent Model Pharmaceutical commercial models across Europe have shifted towards hybrid engagement structures and greater use of Contract Sales Organisations (CSOs), increasing flexibility in how field teams are deployed.¹ ² Recruitment patterns have diversified in parallel. In the UK, representatives are not required to hold medical, pharma…

Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research to late-stage clinical supply without exploding timelines or cost of goods. At the same time, the field is confronting familiar constraints: viral-vector bottlenecks, payload limits, and the risk that DNA elements that are useful for bacterial cloning can become unwanted baggage when the DNA is used as starting material for therapeutics...
Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research to late-stage clinical supply without exploding timelines o…

Workplace attrition threatens operational continuity and clinical trial timelines for life science professionals. The recent shift to remote and decentralized trials presents unique challenges. Fuelled by systemic issues like burnout and depersonalization, and the unique pressures of data-intensive remote work, traditional retention strategies are failing. AI-augmented managed service providers (MSPs) offer a predictive alternative that transforms retention into proactive strategies. Modern health care professionals use deep learning to find hidden patterns and analyze workloads. By scheduling against real-world volatility, they can identify attrition risk and incorporate targeted interventions. Ultimately, they create a more resilient workforce. Organizations must vet, implement and measure the ROI of these strategic partnerships. ...

The global digital stethoscopes market is expected to grow at a compound annual growth rate (CAGR) of approximately 6% during the forecast period, reflecting the ongoing transformation of healthcare delivery systems and the increasing demand for advanced diagnostic technologies.
Market Outlook and Growth Trajectory The global digital stethoscopes market is expected to grow at a compound annual growth rate (CAGR) of approximately 6% during the forecast period, reflecting the ongoing transformation of healthcare delivery systems and the increasing demand for advanced diagnostic technologies. As healthcare providers shift toward data-driven and remote care models, digital stethoscopes are gaining prominence as essential tools for accurate and efficient patient assessment. Get Free Sample Repor…

Safety data overload in pharmacovigilance occurs when drug-safety teams receive extremely large volumes of safety information—such as ICSRs, literature reports, EHR data, and social-media inputs—making it difficult to quickly identify genuine safety signals. Excessive and often low-quality data, including duplicates and inconsistencies, can create noise, increase analyst workload, and delay critical risk-management decisions. This challenge affects signal detection and assessment by causing false positives, alert fatigue, and slower regulatory responses. To address it, organizations are increasingly adopting AI-driven analytics, data standardization, automated deduplication, and advanced signal-detection tools to prioritize meaningful safety insights and ensure efficient pharmacovigilance operations.

Digital Pharmaceutical Supply Chain Management Market Set to Grow at 9% CAGR Amid Rising Demand for Transparency and Drug Traceability
Market Overview The digital pharmaceutical supply chain management market is projected to expand at a compound annual growth rate (CAGR) of approximately 9% between 2025 and 2030, reflecting the growing transition toward technology-driven supply chain ecosystems in the pharmaceutical industry. As pharmaceutical supply networks become more complex and globalized, organizations are increasingly adopting digital technologies to improve visibility, efficiency, and operational resilience. Pharmaceutical companies face mounting pressure to maintain product integrity, ensure regulatory compliance, and quickly respond to fluctuating market demands. Digital supply ch…

Post-Marketing Surveillance (PMS), also known as Phase IV monitoring, plays a critical role in evaluating a drug’s safety, effectiveness, and real-world performance after regulatory approval. While pre-approval clinical trials involve limited and controlled patient populations, PMS monitors medicines in broader and more diverse real-world settings, helping detect rare adverse reactions, long-term risks, and drug interactions that may not appear during earlier trials. Through continuous pharmacovigilance activities such as adverse event reporting, observational studies, and patient registries, PMS provides valuable data that guides regulatory actions, including label updates, boxed warnings, risk-management plans, or even market withdrawal when serious safety concerns arise.
What Is Post‑…

Joint Clinical Assessment JCA is a new EU level clinical evaluation process under Regulation 2021 2282. Mandatory from January 2025 for oncology and advanced therapies, it harmonises comparative clinical assessments across member states. Running in parallel with EMA review, JCA reshapes evidence strategy, trial design, and market access planning across pharma and biotech.
The introduction of Joint Clinical Assessment JCA marks one of the most significant regulatory and market access changes in the European pharmaceutical landscape in decades. Established under the European Health Technology Assessment Regulation Regulation 2021 2282, JCA is reshaping how clinical evidence is assessed across EU member states. For professionals working in regulatory affairs, market access, HEOR, clinical dev…

Pharmaceutical sales in the UK are undergoing a gradual but meaningful shift in who represents medicines to healthcare professionals. Increasingly, companies are recruiting sales representatives without traditional medical or scientific backgrounds. This evolution, driven in part by changing commercial models and the growth of Contract Sales Organisations (CSOs) - reflects broader expansion across the UK and European pharmaceutical outsourcing market.
Pharmaceutical sales in the UK are undergoing a gradual but meaningful shift in who represents medicines to healthcare professionals. Increasingly, companies are recruiting sales representatives without traditional medical or scientific backgrounds. This evolution, driven in part by changing commercial models and the growth of Contract Sales O…

Alkermes is a fully integrated biopharmaceutical company headquartered in Dublin, Ireland, with R&D and manufacturing facilities in the U.S. With $1.5B in annual revenue, Alkermes has focused for more than 30 years on developing innovative treatments for psychiatric and neurological disorders. At a time when 40% of procurement teams said manual and inefficient processes are holding them back[1], the company turned to JAGGAER to improve spend visibility and create standardized workflows across departments and sites. The result has increased usability and brought a 23% reduction in purchase order (PO) processing costs and a 32% reduction in cycle times.
Alkermes is a fully integrated biopharmaceutical company headquartered in Dublin, Ireland, with R&D and manufacturing facilities in the…

From Passive Endpoints to Engineered Outcomes: The Clinical Case for Resilience in Oncology - By Nicolas Wolikow, Founder & CEO, Cure51
The integration of artificial intelligence and advanced computational modeling has already catalyzed a structural shift in global healthcare. In oncology, this "Precision Medicine" era has successfully moved the needle on early diagnostics and molecularly targeted therapies. However, while we have become experts at targeting the tumor, we are only just beginning to understand the host’s capacity for survival. The next evolution in cancer care will not be defined solely by the discovery of new molecules, but by the systematic deconstruction of survival itself. To truly advance, the industry must transition from viewing survival as a passive statistical endpo…

Clinical data review and analysis ensures accuracy, compliance, and actionable insights in clinical trials. By combining rigorous data validation with advanced analytics, pharma teams can enhance trial integrity, support regulatory approval, and accelerate drug development timelines.
Clinical data review and analysis is a cornerstone of modern pharmaceutical research and development. With the growing complexity of clinical trials and regulatory requirements, accurate and efficient data management has never been more critical. Understanding the process from raw data collection to final analysis ensures that clinical findings are reliable, actionable, and compliant with global standards. At its core, clinical data review involves the systematic examination of trial data for accuracy, complete…

Learn how clinical trial supply management works, including forecasting, logistics, inventory control, and risk mitigation to ensure uninterrupted trials.
Clinical trial supply management is the backbone of successful clinical research, ensuring that investigational products reach study sites on time, in optimal condition, and in compliance with global regulations. Effective clinical trial supply chain management ensures trials run smoothly, safeguards patient safety, and preserves the integrity of clinical data. Modern clinical trials, including decentralized designs, global studies, and personalized therapies, demand a deep understanding of clinical supply operations. Leveraging advanced technology and AI-driven tools is essential to maintain operational efficiency, regulatory complia…

Learn what clinical data review and analysis are, why it matters in clinical trials, key steps involved, and best practices to ensure data quality and compliance
Clinical data review is the continuous process of evaluating clinical trial data for accuracy, completeness, consistency, and clinical relevance as it is collected, ensuring data quality and early identification of issues. Clinical data analysis builds on this validated data by applying analytical and statistical methods to uncover patterns, trends, and insights that inform clinical development, operational decisions, and regulatory outcomes across the trial lifecycle. Clinical trials today generate unprecedented volumes of data, far beyond what traditional review and analysis models were designed to handle. This expans…

The audits are the main regulatory tool for many industries especially the medical device and pharmaceutical sector. The audits, whether they are internal, vendor-based, or regulatory, should be done by organizations to show that they comply with the strict quality standards of cGMP, QMS, and CAPA. The article exposes the ins and outs of audits, regulatory inspections, and compliance requirements, with a special emphasis on FDA inspections and the QSIT (Quality System Inspection Technique) approach.
Introduction to Audits In the fields of pharmaceuticals and medical devices where regulation is imposed, compliance with the quality standards set by the authorities is vital for the protection of the products from dangerous effects and ensuring therapeutic efficiency. Audits form an integral pa…